Description
This notice announces the Department of Veterans Affairs’ intent to sole‑source a one‑year contract for the supply of two high‑value radiopharmaceuticals—Lutathera® (Lu‑177 dotatate) and Pluvicto® (Lu‑177 vipivotide tetraxetan)—to the Lebanon VA Medical Center’s Nuclear Medicine Department. The contractor must deliver ready‑to‑use unit‑dose packages, manage inventory, provide quality‑control documentation, and support emergency deliveries, all at no cost to the Government. The procurement will be negotiated under FAR 8.4 with Novartis Pharmaceuticals Corporation as the preferred source, but the VA is gathering capability statements from any interested vendors.
• Provide 8 Lutathera and 48 Pluvicto doses annually (200 mCi each) with on‑site or remote consultation, QC testing, and packaging.
• Deliver doses > 1 hour before the calibrated administration time, with emergency‑delivery capability outside normal business hours.
• Maintain all required NRC, FDA, DOT, OSHA, HIPAA, and VA certifications; handle returns, credits, and disposals at no cost to the Government.
• Contract type is Firm‑Fixed‑Price for the period 01 Jan 2027 – 31 Dec 2027, with strict performance and delivery requirements.